Eli Lilly Canada

lilly.ca

Globally, Eli Lilly and Company employs approximately 41,000 people and markets medicines in 120 countries. With major Research and Development facilities in six countries and clinical research conducted in more than 55 countries, Lilly’s work continues to break new ground, placing it on the leading edge in many of today’s most important areas of health care research.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET, PHARMA TECH

MTTI OBTAINS FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG (IND) FOR HÜRTHLE CELL THYROID CANCER

Molecular Targeting Technologies, Inc | December 09, 2022

news image

Molecular Targeting Technologies, Inc. a clinical stage radiopharmaceutical therapy company focused on therapies for rare diseases, announced today the allowance of an Investigational New Drug application by the U.S. Food and Drug Administration. It is now waiting for Institutional Review Board approval. Once approved by IRB, it will enable a Phase I/II clinical study of the Safety, Dosimetry and Efficacy of EBTATE in adult patients with metastatic, radioactive iodine non-responsive Hürthle...

Read More

Business Insights

LABCORP COMPLETES ACQUISITION OF PERSONAL GENOME DIAGNOSTICS

Labcorp | February 21, 2022

news image

Labcorp a leading global life sciences company, announced that it has closed its acquisition of Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products. The addition of PGDx and its technology complements and accelerates Labcorp’s existing liquid biopsy capabilities and expands Labcorp’s leading oncology portfolio of next-generation sequencing (NGS)-based genomic profiling capabilities, posit...

Read More

Business Insights

FUSION PHARMACEUTICALS AND NIOWAVE ANNOUNCE ACTINIUM-225 COLLABORATION AND SUPPLY AGREEMENT

Fusion Pharmaceuticals Inc. | June 13, 2022

news image

Fusion Pharmaceuticals Inc. a clinical-stage oncology company focused on developing next-generation radio pharmaceuticals as precision medicines, and Niowave, Inc., a manufacturer of medical radioisotopes from radium and uranium, today announced that the companies have entered into a collaboration and supply agreement for the development, production, and supply of actinium-225. Under the agreement, Fusion will invest up to $5 million in Niowave to further develop their technology to increase cur...

Read More

Business Insights

OPTIMIZERX ACQUIRES EVINCEMED, A SPECIALTY DRUG PRESCRIPTION INITIATION PLATFORM

OptimizeRx Corporation | March 16, 2022

news image

OptimizeRx Corp. a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced a definitive agreement to acquire the EvinceMed platform and related assets. EvinceMed is a leader in delivering end-to-end automation for specialty pharmaceutical transactions. The acquisition includes the full Market Access Management Platform supporting pharma manufacturers, hub providers and pharmacies to improve patient access, speed to therapy and activation of af...

Read More
news image

PHARMACY MARKET, PHARMA TECH

MTTI OBTAINS FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG (IND) FOR HÜRTHLE CELL THYROID CANCER

Molecular Targeting Technologies, Inc | December 09, 2022

Molecular Targeting Technologies, Inc. a clinical stage radiopharmaceutical therapy company focused on therapies for rare diseases, announced today the allowance of an Investigational New Drug application by the U.S. Food and Drug Administration. It is now waiting for Institutional Review Board approval. Once approved by IRB, it will enable a Phase I/II clinical study of the Safety, Dosimetry and Efficacy of EBTATE in adult patients with metastatic, radioactive iodine non-responsive Hürthle...

Read More
news image

Business Insights

LABCORP COMPLETES ACQUISITION OF PERSONAL GENOME DIAGNOSTICS

Labcorp | February 21, 2022

Labcorp a leading global life sciences company, announced that it has closed its acquisition of Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products. The addition of PGDx and its technology complements and accelerates Labcorp’s existing liquid biopsy capabilities and expands Labcorp’s leading oncology portfolio of next-generation sequencing (NGS)-based genomic profiling capabilities, posit...

Read More
news image

Business Insights

FUSION PHARMACEUTICALS AND NIOWAVE ANNOUNCE ACTINIUM-225 COLLABORATION AND SUPPLY AGREEMENT

Fusion Pharmaceuticals Inc. | June 13, 2022

Fusion Pharmaceuticals Inc. a clinical-stage oncology company focused on developing next-generation radio pharmaceuticals as precision medicines, and Niowave, Inc., a manufacturer of medical radioisotopes from radium and uranium, today announced that the companies have entered into a collaboration and supply agreement for the development, production, and supply of actinium-225. Under the agreement, Fusion will invest up to $5 million in Niowave to further develop their technology to increase cur...

Read More
news image

Business Insights

OPTIMIZERX ACQUIRES EVINCEMED, A SPECIALTY DRUG PRESCRIPTION INITIATION PLATFORM

OptimizeRx Corporation | March 16, 2022

OptimizeRx Corp. a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced a definitive agreement to acquire the EvinceMed platform and related assets. EvinceMed is a leader in delivering end-to-end automation for specialty pharmaceutical transactions. The acquisition includes the full Market Access Management Platform supporting pharma manufacturers, hub providers and pharmacies to improve patient access, speed to therapy and activation of af...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us